)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
ALX Oncology
ALX Oncology (ALXO) investor relations material
ALX Oncology 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary15 Jan, 2026
Program highlights and strategic focus
Advanced two differentiated clinical-stage programs: Evorpacept (CD47 inhibitor) and ALX 2004 (EGFR-targeted ADC), both showing strong progress in trials and multiple clinical milestones expected in 2026.
Collaborations with Jazz and Sanofi further validated Evorpacept’s efficacy in combination therapies, including bispecifics and hematologic malignancies.
Aspen breast trial is actively enrolling, targeting post-Enhertu HER2-positive patients, with interim data expected in Q3 2026.
Projected cash runway extends into Q1 2027, supporting key milestones such as ALX2004 safety data and ASPEN-Breast trial results.
Partnerships and internal R&D optimization are central to advancing both assets.
Clinical data and biomarker-driven approach
Evorpacept demonstrated validated mechanism and safety, with focus on breast cancer, multiple myeloma, and high response rates in HER2-positive gastric and breast cancer, especially in CD47-overexpressing subgroups.
Rituxan/Evorpacept combinations in lymphoma demonstrated high complete response rates, up to 92% in first-line settings.
Safety profile across 750+ patients is manageable and reversible, with adverse events comparable to control arms.
Evorpacept blocks CD47-SIRPA interaction, enhancing macrophage-mediated phagocytosis, and its inactive Fc design minimizes toxicity.
CD47 overexpression is a negative prognostic biomarker, supporting patient selection strategies.
Market opportunity and trial design
HER2-positive breast cancer post-Enhertu represents a $2–$4 billion market, with 20,000 addressable patients in the U.S.
Aspen breast trial is an 80-patient, single-arm study with primary endpoint of response rate; interim data expected Q3 2026.
Future plans include a phase III randomized trial, likely in CD47-selected patients, to support registration.
Multiple myeloma collaboration with Sanofi (Sarclisa) is progressing, with positive data supporting advancement.
ALX2004 phase 1 trial enrolling in multiple EGFR-expressing solid tumors, with potential for accelerated approval.
Impact of CD47 biomarker on evorpacept breast cancer strategy
ALX2004's competitive edge in EGFR ADC space
What are the biggest risks to 2026 registrational goals?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next ALX Oncology earnings date
Q4 20255 Mar, 2026
ALX Oncology
Next ALX Oncology earnings date
Q4 20255 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on developing therapies that target the CD47 checkpoint pathway, which plays a critical role in cancer cells' ability to evade the immune system. The company's lead product candidate, evorpacept, is designed to block CD47 and is being developed in combination with other anti-cancer agents. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage